Genetic Technologies Ltd. - GENE STOCK NEWS

Genetic Technologies Limited (NASDAQ: GENE) announces the publication of a validation study in the European Journal of Cancer Prevention that evaluates the performance of its geneType ovarian cancer test. This 10-year prospective cohort study, involving over 190,000 women, demonstrates that the geneType test significantly enhances the identification of women at increased risk for ovarian cancer. Key findings include the ability to identify the top 20% of women with over a 40% increased 10-year risk. The results promote early intervention and improved patient outcomes for ovarian cancer, a leading cause of cancer-related death in women.

Genetic Technologies Limited (NASDAQ: GENE; ASX: GTG) reported a significant 375% revenue increase to A$1.93 million for Q1 FY23, driven by its core brands: geneType, EasyDNA, and AffinityDNA. Cash receipts were A$2.06 million with a cash balance of A$7.95 million. The company announced strategic acquisitions to strengthen its direct-to-consumer channel and expanded commercialization efforts for its geneType multi-risk test. Partnerships with healthcare providers and the development of a pharmacy channel were highlighted, along with progress in the US market aimed at securing reimbursement for its tests.

Genetic Technologies Limited (NASDAQ:GENE) will feature in an upcoming interview on The RedChip Money Report airing on Bloomberg TV on October 15, 2022, at 7 p.m. ET. CEO Simon Morriss will discuss the company’s expanded test portfolio, global partnerships, and five consecutive quarters of revenue growth. As a leader in genomics-based health tests, Genetic Technologies aims to improve health outcomes through its innovative risk assessment products, notably in oncology and cardiovascular sectors. The interview will be available online for further insights.

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) announced the publication of a paper in the Journal of Precision Medicine that underscores the benefits of its GeneType Risk Prediction Tools in precision medicine. The study demonstrates that the GeneType Risk Assessment Test for breast cancer outperforms traditional assessments, achieving a 9-fold improvement in identifying at-risk women. The paper emphasizes integrating genomic data with traditional risk factors for enhanced patient outcomes, supporting earlier interventions.

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) reports significant progress in U.S. market operations. The company is engaging with 11 U.S. payer groups, targeting coverage for its geneType Breast Cancer Risk Assessment Test, which could save the U.S. healthcare system $1.4 billion annually. Other highlights include partnerships with 19 Concierge Medicine practices, re-engagement with 1,600 previous customers, and the establishment of a U.S. operations team for EasyDNA product sales. The Melbourne lab has received CLIA certification as a High Complexity Laboratory, facilitating U.S. sample testing.

Genetic Technologies Limited (NASDAQ: GENE) reported a remarkable revenue increase of 5,536% for the year ending June 30, 2022, totaling A$6.674 million. The growth is attributed to the acquisition of EasyDNA and the recent addition of AffinityDNA, enhancing their portfolio of genetic tests.

Key initiatives include reimbursement discussions for the geneType Breast Cancer Risk Assessment test, aiming for widespread adoption. The company plans to expand their offerings, with over 50 tests now available across 14 categories, positioning GENE to capitalize on a rapidly growing market.

Genetic Technologies Limited (NASDAQ: GENE) reported a solid performance for Q4 FY22, with cash receipts rising by 43% to A$3.5 million, including a R&D tax incentive of A$1.4 million. Customer revenue reached A$2 million, an increase of 2.3% from the previous quarter, and cash reserves were A$11.7 million as of June 30, 2022. The company acquired AffinityDNA, enhancing its European sales channels, and launched discussions with U.S. payers for its geneType risk tests, which now operate in 24 clinics. The outlook remains optimistic, targeting multi-billion-dollar opportunities in genetic testing.

Genetic Technologies Limited (NASDAQ: GENE) has partnered with Melbourne's Siles Health to integrate the geneType Multi-Risk Test into their obstetrics and gynaecology practices. This initiative aims to enhance personalized patient care by identifying high-risk patients for various serious diseases.

Siles Health, treating over 15,000 patients each year, will incorporate genetic counseling services for actionable patient pathways. The geneType Multi-Risk Test assesses risks for diseases like breast and colorectal cancer. The partnership represents a key step in GENE's commercialization strategy, promising improved health outcomes for patients.

Genetic Technologies Limited (NASDAQ: GENE) has completed its acquisition of AffinityDNA's direct-to-consumer eCommerce business and distribution rights, initially announced on May 16, 2022. This strategic move aims to enhance GENE's direct-to-consumer capabilities and tap into the growing consumer genomics market. The acquisition adds 51 tests across 14 categories to GENE's portfolio, including non-invasive prenatal testing and lifestyle genomics. GENE retains AffinityDNA's team in the UK and plans to leverage its market presence to boost sales of its geneType Multi Risk test.